Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

ProKidney Corp (PROK)

NASDAQ
Currency in USD
Disclaimer
2.530
-0.190(-6.99%)
Closed
After Hours
2.730+0.200(+7.905%)
PROK Scorecard
Unusual Post-Market activity
Fair Value
Unlock Value
Day's Range
2.3902.850
52 wk Range
1.12013.510
Prev. Close
2.53
Open
2.72
Day's Range
2.39-2.85
52 wk Range
1.12-13.51
Volume
1,149,701
Average Volume (3m)
701,016
1-Year Change
-77.9%
Shares Outstanding
61,621,330
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

1.520
STI
+10.95%
0.8781
MIRA
+2.10%
2.140
LASE
+0.94%
0.7600
PBM
+1.74%
1.100
ICCT
-1.79%
How do you feel today about PROK?
Vote to see community's results!
or
  • ProKidney exec sells over $43k in company shares
    • ByInvesting.com
  • ProKidney exec sells over $146k in company stock
    • ByInvesting.com

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.